ERBB2 and breast carcinoma: Unlike the molecularly targeted treatment strategies available for hormone receptor expressing or HER2 amplified subsets of breast cancer, effective targeted therapies for TNBC that improve survival have yet to be developed, and cytotoxic chemotherapy remains the main therapy for TNBC [4].